---
title: "Glucose-Linked Chlorin E6-Conjugated Trastuzumab for Targeted Photodynamic Therapy in HER2-Posit"
id: "plos-one-4-anti-cancer-effect-of-a-novel-photodynamic-therapy-using-glucose-linked-chlorin-e6-conjugated-trastuzumab-for-her2-positive-gastrointestinal-cancers"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-4-anti-cancer-effect-of-a-novel-photodynamic-therapy-using-glucose-linked-chlorin-e6-conjugated-trastuzumab-for-her2-positive-gastrointestinal-cancers"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346567"
published_at: "2026-04-03T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Glucose-Linked Chlorin E6-Conjugated Trastuzumab for Targeted Photodynamic Therapy in HER2-Posit
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-4-anti-cancer-effect-of-a-novel-photodynamic-therapy-using-glucose-linked-chlorin-e6-conjugated-trastuzumab-for-her2-positive-gastrointestinal-cancers
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346567)
- **Published At:** 2026-04-03T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
by Makiko Sasaki, Mamoru Tanaka, Akihiro Nomoto, Ryusei Yamasaki, Tomokazu Yoshimura, Shigenobu Yano, Yasunari Sasaki, Yuki Kojima, Taketo Suzuki, Hirotada Nishie, Keiji Ozeki, Takaya Shimura, Eiji Kubota, Hiromi Kataoka Photodynamic therapy (PDT) is an anti-cancer therapy that employs a photosensitizer (PS) and an optimal wavelength of light, causing a photochemical reaction that releases reactive oxygen species, thereby inducing cancer cell death via oxidative stress. Because light irradiation is limited to the tumor site, PDT has minimal adverse effects. The cancer cell selectivity of the PS is important for reducing damage to the normal mucosa caused by scattered light. Antibody-drug conjugates (ADC) are novel anti-cancer therapies that combine a monoclonal tumor-surface-receptor-targeting antibody with a drug bonded through chemical linkers. ADCs enable the targeted delivery of a variety of drugs to cancer cells while minimizing their delivery to healthy tissues. One such tumor surface receptor is the human epidermal growth factor receptor 2 (HER2), which is of interest in the treatment of many cancers, including gastrointestinal cancer.
## Clinical Analysis & Structured Key Points
Targeted photodynamic approach in HER2-positive gastrointestinal cancer: Study design and objective: - The work reports development and evaluation of a novel photosensitizer conjugate for photodynamic therapy (PDT) aimed at improving tumor selectivity and minimizing surrounding mucosal damage. - Researchers engineered a glucose-linked chlorin e6 conjugated to trastuzumab (G-Ce6-trastuzumab), pairing a tumor-targeting antibody with a photosensitizer linked via a glucose moiety. Molecular construct and rationale: - G-Ce6-trastuzumab combines an established photosensitizer, chlorin e6 (Ce6), with a glucose linker and the anti-HER2 antibody trastuzumab. - The design intends to direct PDT activity more specifically to HER2-expressing cancer cells, leveraging both antibody-targeting and the intracellular routing of the photosensitizer. Experimental models and comparison: - The anti-cancer effects were assessed in vitro using two cell lines that differ in HER2 expression: NCI-N87 (high HER2) and MKN-45 (low HER2). - The internalization of G-Ce6-trastuzumab occurred at intracellular organelles within cancer cells. Assessment of cytotoxicity: - Cell viability was measured with the WST-8 assay following PDT. - Results indicated a significantly greater cytotoxic effect of G-Ce6-trastuzumab compared with the conventional photosensitizer G-Ce6 in HER2-high-expression cells. - The implication is enhanced selectivity for HER2-high-expressing cells, potentially reducing damage to adjacent normal mucosa. Context and interpretation: - The study positions G-Ce6-trastuzumab as a promising photosensitizer for PDT, aiming to combine targeted antibody delivery with light-activated cytotoxicity. - The authors suggest that strong selectivity for HER2-high-expression cells could translate into improved therapeutic precision for gastrointestinal cancers expressing HER2. Limitations and reporting constraints: - The provided content focuses on in vitro findings in two cell lines and does not report in vivo outcomes, comprehensive safety data, or clinical performance. - The source does not include explicit clinical endpoints, dosing parameters, or translational feasibility assessments beyond the cellular model. Open questions and uncertainty: - Whether the enhanced cytotoxicity observed in vitro translates to in vivo tumor control and tolerability remains to be established.
## Related Clinical Research

- [Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer](https://medichelpline.com/clinical-feed/nejm-11-trastuzumab-deruxtecan-in-residual-her2-positive-early-breast-cancer.md)
- [Stepwise Molecular Profiling Reveals Co-occurring EGFR L858R and HER2 Amplification in NSCLC](https://medichelpline.com/clinical-feed/pubmed-42681853.md) (DOI: 10.12659/AJCR.953829)
- [HER2-Targeted Therapy in Metastatic Colorectal Cancer: Evidence, Testing, and Sequencing](https://medichelpline.com/clinical-feed/pubmed-42663748.md) (DOI: 10.1007/s12029-026-01564-1)
- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development](https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.